Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not beDallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron.” As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remai ...